shutterstock-128145248-web
Adam Gregor / Shutterstock.com
31 July 2014Americas

Pfizer acquires Baxter vaccines for $635m

Pfizer has entered into a definitive agreement to acquire two vaccines marketed by US biotechnology company Baxter International for $635 million.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
12 November 2020   The European Commission has approved a fourth contract with pharmaceutical companies Pfizer and BioNTech, following their revelation that they had developed a vaccine that could potentially prevent more than 90% of people from becoming infected by COVID-19.
Americas
16 November 2020   American healthcare multinational Baxter has accused B.Braun of patent infringement and fraudulent misrepresentation in an on-going dispute over products used to treat acute kidney injury.

More on this story

Big Pharma
12 November 2020   The European Commission has approved a fourth contract with pharmaceutical companies Pfizer and BioNTech, following their revelation that they had developed a vaccine that could potentially prevent more than 90% of people from becoming infected by COVID-19.
Americas
16 November 2020   American healthcare multinational Baxter has accused B.Braun of patent infringement and fraudulent misrepresentation in an on-going dispute over products used to treat acute kidney injury.

More on this story

Big Pharma
12 November 2020   The European Commission has approved a fourth contract with pharmaceutical companies Pfizer and BioNTech, following their revelation that they had developed a vaccine that could potentially prevent more than 90% of people from becoming infected by COVID-19.
Americas
16 November 2020   American healthcare multinational Baxter has accused B.Braun of patent infringement and fraudulent misrepresentation in an on-going dispute over products used to treat acute kidney injury.